Why Cheech And Chong’s $100 Million Cannabis Empire Is No Joke https://t.co/t8OJEQAhQn https://t.co/saDctjeKuk ...

Business Overview - Cheech & Chong 公司销售含有 THC 的食品、饮料和大麻产品 [1] - 这些产品为公司带来了可观的收入 [1]

Core Insights - The article highlights the top-performing leveraged and inverse ETFs from the previous week, showcasing significant gains across various sectors, particularly in cryptocurrency, cannabis, and gold mining industries. Group 1: Top Performing ETFs - CEFZ (RiverNorth Active Income ETF) achieved approximately 56% gains, marking its fourth consecutive week at the top, benefiting from a shift to ETF status [1] - ETHD (ProShares UltraShort Ether ETF) ranked second with over 21% weekly gains, influenced by macroeconomic indicators and a recent dip in ether prices [2] - MSOX (AdvisorShares MSOS Daily Leveraged ETF) saw around 21% weekly returns, driven by momentum for cannabis legalization and positive financial results from cannabis firms [3] - BABX (GraniteShares 2x Long BABA Daily ETF) gained over 18% weekly, supported by a revenue surge from Alibaba due to China's AI boom [4] - SBIT (ProShares UltraShort Bitcoin ETF) recorded approximately 15% weekly gains, following a lower-than-expected Producer Price Index [5] - IONX (Defiance Daily Target 2X Long IONQ ETF) benefited from B. Riley's "Buy" rating and technological advancements, contributing to its stock price increase [6] - GDXU (MicroSectors Gold Miners 3X Leveraged ETN) returned over 14%, driven by a weak dollar and expectations of a US Fed rate cut [7] - BOIL (ProShares Ultra Bloomberg Natural Gas) gained more than 12% as natural gas prices rose amid tighter US supplies [8] - SETH (ProShares Short Ether ETF) achieved over 10% weekly gains, designed to profit from a decline in Ether's price [9] - JNUG (Direxion Daily Junior Gold Miners Index Bull 2x Shares) returned approximately 10%, focusing on junior gold miners [9]

LONG BEACH, Calif. and TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest-growing, vertically-integrated cannabis companies in the U.S., today announced with great sadness the passing of Mr. George Raveling, a valued member of the Company’s Board of Directors and the Glass House family. Mr. Raveling joined the Board in 2021 when the company went public, bringing with hi ...

Core Insights - Avicanna Inc. has successfully completed its first export of organic certified non-psychoactive CBD dominant cannabis flower to Switzerland through its subsidiary Santa Marta Golden Hemp SAS, marking a significant milestone for the company [1][4] - This export expands the Aureus branded products to 20 international markets and Avicanna products to 23 markets, showcasing the company's ability to navigate complex regulatory environments for international commercialization [4][6] Company Developments - In 2024, Avicanna improved internal practices and local infrastructure at Santa Marta Golden Hemp SAS to enhance its portfolio of premium organic flower, responding to the increasing demand for medical cannabis in Europe and Australia [3] - The export included three proprietary cannabis varieties registered in Colombia, further validating the company's expertise in the cannabis sector [4] Product and Market Information - The Aureus brand encompasses a range of raw materials and active pharmaceutical ingredients (APIs) including CBD, CBG, and THC, which are essential for the company's supply chain and product offerings in consumer retail, medical cannabis, and pharmaceuticals [5][11] - Santa Marta Golden Hemp SAS has received Good Agricultural and Collection Practices (GACP) and Organic certifications under the USDA National Organic Program, ensuring high-quality input materials for various industries [6] Operational Capacity - The SMGH facility spans approximately 300,000 square feet with an extraction capacity of 300 kg, yielding around 26,400 kg annually, which supports the company's production capabilities [6]

Core Viewpoint - Herbal Dispatch Inc. is conducting a non-brokered private placement aiming to raise up to $1,000,000, with strong interest potentially leading to an oversubscription of up to $2,000,000 [1][2]. Group 1: Private Placement Details - The company plans to issue up to 20,000,000 units at a price of $0.05 per unit, with gross proceeds expected to reach $1,000,000 [1]. - Due to high demand, the private placement may be oversubscribed, allowing for the issuance of up to 40,000,000 units for gross proceeds of up to $2,000,000, which has been approved by the Canadian Securities Exchange [2]. - The closing of the private placement is anticipated to occur around September 19, 2025 [2]. Group 2: Use of Proceeds - Proceeds from the private placement and any oversubscription will be allocated for working capital, including inventory purchases to support export sales growth, supplier payments, and upcoming principal loan payments [3]. Group 3: Company Overview - Herbal Dispatch Inc. operates leading cannabis e-commerce platforms, focusing on providing high-quality cannabis products at affordable prices [4]. - The company's flagship marketplace, herbaldispatch.com, offers exclusive access to small-batch craft cannabis and a variety of product formats [4].

Industry Trend - Cannabis companies are increasingly using an arcane legal tool [1] - Competition in the weed industry is forcing former startups to restructure their debts [1]

Core Insights - High Tide's Canna Cabana retail cannabis store has shown consistent growth, reaching 203 locations across Canada by July 2025, with significant expansions in Alberta and Ontario [1][8] - Canna Cabana achieved a 12% market share in the cannabis retail market, with stores generating 2.3 times the revenue of competitors [2][8] - The Canadian legal cannabis market was valued at $3.25 billion in 2024, with a projected CAGR of 12% from 2025 to 2030, driven by federal legalization and increased health awareness [3] Company Performance - High Tide's shares increased by 76.2% over the past year, significantly outperforming the industry growth of 3.3% and the S&P 500's 15.5% [7] - The company reported approximately $6.8 million in retail sales from April 17 to April 20, 2025 [2] Market Dynamics - The Ontario government increased the cannabis retail store cap from 75 to 150 locations, enhancing High Tide's growth potential in the largest cannabis market in Canada [3][8] - Peer companies like Village Farms and Aurora Cannabis are also experiencing significant growth, with Village Farms reporting a 690% increase in international medical export sales and Aurora Cannabis seeing an 85% rise in international medical cannabis sales [4][6] Valuation Metrics - High Tide currently trades at a forward Price-to-Sales (P/S) ratio of 0.55X, compared to the industry average of 5.60X, indicating a discounted valuation [9]

Group 1 - The cannabis industry is experiencing increased speculation regarding the potential reclassification of cannabis from a Schedule 1 to a Schedule 3 substance, which could have significant implications for the market [1] - Comments regarding the reclassification gained credibility following statements made by President on August 11th, indicating a shift in regulatory perspective [1] Group 2 - The author of the article has extensive experience in finance and investment banking, including founding a nationwide investment banking firm and writing multiple publications on cannabis stocks [1]

Core Insights - Momentum investors focus on "buying high and selling higher" rather than traditional strategies of buying low and waiting for recovery [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [2] Group 1: Investment Strategy - A safer investment approach involves targeting bargain stocks that exhibit recent price momentum [3] - The Zacks Momentum Style Score aids in identifying strong momentum stocks by analyzing price and earnings trends [3] Group 2: MariMed Inc. (MRMD) Analysis - MariMed Inc. (MRMD) has shown significant price momentum, with a four-week price change of 58% and a 12-week gain of 114.2% [4][5] - MRMD has a high beta of 3, indicating it moves 200% more than the market in either direction, suggesting strong volatility [5] - The stock has a Momentum Score of B, indicating a favorable time to invest [6] Group 3: Earnings and Valuation - MRMD has received a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which attract more investor interest [7] - The stock is currently trading at a Price-to-Sales ratio of 0.38, indicating it is undervalued at 38 cents for each dollar of sales [7] Group 4: Additional Opportunities - Besides MRMD, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8] - Zacks offers over 45 Premium Screens tailored to different investing styles, which can help identify potential winning stocks [9]